Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Cascione M, Wynn D, Barbato LM, Pestreich L, Schofield L, McCague K